
| Pair Name | Piperlongumine, Bortezomib | ||
| Phytochemical Name | Piperlongumine (PubChem CID: 637858 ) | ||
| Anticancer drug Name | Bortezomib (PubChem CID: 387447 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Piperlongumine, Bortezomib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Endoplasmic reticulum stress | |||
| Gene Regulation | Up-regulation | Expression | ATF4 | hsa468 |
| Up-regulation | Expression | ATF6 | hsa22926 | |
| Up-regulation | Expression | XBP1 | hsa7494 | |
| Up-regulation | Expression | DDIT3 | hsa1649 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | KKU-M055 | Intrahepatic cholangiocarcinoma | Homo sapiens (Human) | CVCL_M258 |
| KKU-213A | Intrahepatic cholangiocarcinoma | Homo sapiens (Human) | CVCL_M261 | |
| Result | Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stress-induced cell death | |||
| No. | Title | Href |
|---|---|---|
| 1 | Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stress-induced cell death. Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan;396(1):109-120. doi: 10.1007/s00210-022-02305-4. | Click |